toxicities and new immune checkpoint inhibitors
Published 5 years ago • 134 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
2:05
checkpoint inhibitors: parallel management of the disease and immune-related toxicities
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
9:55
immune checkpoint inhibitors in acute leukemia
-
1:34
checkpoint inhibitors and their potential role in mm
-
3:30
determining effective combinations of immune checkpoint inhibitors for lymphoma
-
1:33
sitc clinical practice guidelines on immune checkpoint inhibitor-related adverse events
-
7:32
current immune checkpoint inhibitor trials in aml/mds
-
1:20
new strategies in aml: checkpoint inhibitors combined with t-cell engagers
-
37:26
cancer immunotherapy basics: understand the science behind this cutting-edge treatment
-
5:33
cancer immune checkpoint inhibitors
-
21:32
bispecific antibodies for t‐cell redirection therapy
-
2:32
the growing role of anti-pd1 inhibitors in the frontline treatment of hl
-
2:15
cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
-
1:13
checkpoint inhibitor/bispecific antibody combo: regn2810 and regn1979 in b-lymphoid malignancies
-
4:40
engraftment syndrome following asct in patients with checkpoint inhibitor treated hodgkin lymphoma
-
2:41
immunotherapy in aml: azacitidine plus checkpoint inhibitors
-
5:20
immuno-oncology agents for mm: checkpoint inhibitors and nk-cells
-
1:25
results of checkmate 039 trial of nivolumab in combination with ipilimumab for hodgkin lymphoma
-
4:55
checkpoint inhibitor combination approaches for aml/mds: an update
-
1:16
controversies surrounding the management and treatment of lymphomas
-
9:02
precision medicine in lymphoma